BRIEF — Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia

Oct 15 (Reuters) — Modus Therapeutics Holding AB (publ): Said On Wednesday Voluntarily Decided, As A Precautionary Measure, To Temporarily Pause Enrollment In Part 2 Of The Ongoing Phase Iia Study Of Sevuparin Within The Co's Program In Ckd With Anemia The Decision Was Made After A Serious Adverse Event In A Patient Treated With Sevuparin Was Reported The Pause Is Not The Result Of A Regulatory Decision Preliminary Assessment Is That The Pause Will Shift The Proof-of-concept Readout From Around The Turn Of The Year 2026/2027 To Q1 2027 Any Effects Of Pause On Costs, Timeline To Be Reflected In Updated Assessment Of Co's Financing That Modus Intends To Present In Q3 Interim Report On November 24, 2026 Source text:... Further company coverage: MODTX.ST (Gdansk Newsroom) ((mailto:gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;)